re: Ann: Appendix 4C - Quarterly Cash Flow - ... Well I'm fairly new to PAB - but do concede that maybe SC1 isn't compelling enough for big pharma, being such a small target market - in the western world anyhow but you never know - a deal could come out of anywhere.
As far as the SP goes - we are being taken down along with all the other bios. We have to hope that the trial later this year is compelling enough for Amgen to strike, and they obviously think a lot of SM6 already.
Then there's the new compound going to clinic. Results later this year - 2014 could end VERY well for holders imo.
Ann: Appendix 4C - Quarterly Cash Flow - March 20, page-16
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $2.652K | 662.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 24059180 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7535838 | 11 |
View Market Depth
| Last trade - 14.10pm 13/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |